pharma · Weight Loss · Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD) · VKTX
Viking Therapeutics
Viking Therapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2012
- Employees
- 60
- Programs
- 6
- Drugs
- 3
- Patents
- 15
Viking Therapeutics projects
6 ClinicalTrials.gov programs sponsored by Viking Therapeutics.
Viking Therapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
VK2735
Viking Therapeutics
Weight Loss
4 trials -
Placebo
Viking Therapeutics
Weight Loss
1 trial -
VK2809
Viking Therapeutics
Hyperlipidemia
1 trial -
VK2809
Viking Therapeutics
NASH - Nonalcoholic Steatohepatitis
1 trial -
VK5211
Viking Therapeutics
Hip Fractures
1 trial -
VK0214
Viking Therapeutics
Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)
1 trial
Frequently asked questions
How many clinical projects does Viking Therapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.